Gilead Sciences (GILD) Tops Q2 EPS by 41c; offers guidance
Tweet
Share
E-mail
Get Alerts GILD Hot Sheet
Price: $124.87 +0.90%
Revenue Growth %: +4.4%
Financial Fact:
Net income: 3.33B
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +4.4%
Financial Fact:
Net income: 3.33B
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Gilead Sciences (NASDAQ: GILD) reported Q2 EPS of $2.01, $0.41 better than the analyst estimate of $1.60. Revenue for the quarter came in at $7 billion versus the consensus estimate of $6.72 billion.
GUIDANCE:
Gilead Sciences sees FY2024 EPS of $3.60-$3.90, versus the consensus of $3.71. Gilead Sciences sees FY2024 revenue of $27.1-27.5 billion, versus the consensus of $27.583 billion.
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Primoris cuts 2026 outlook on renewables cost overruns, COO exits
- IBM joins OpenAI cyber program, launches app security service
- Comfort Systems USA names new COO and Chief Strategy Officer
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
